FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Details

Language :

English

ISSN :

00064971 and 15280020

Volume :

140

Issue :

1, Number 1 Supplement 1

Database :

Supplemental Index

Journal :

Blood

Publication Type :

Periodical

Accession number :

ejs62897880

Full Text :

https://doi.org/10.1182/blood-2022-163099